Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 8Phase 3 5Phase 1/2 4Phase 4 1

Status

Completed 4Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 4

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 4Hormone Refractory Prostate Cancer 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × radium Ra 223 dichloride × Clear all
NCT07611110 2026-05-28

VECTRA-01

AstraZeneca

Phase 3 Recruiting
670 enrolled
Genitourinary

Prostatic Neoplasms

NCT00699751 2026-02-23

ALSYMPCA

Bayer

Phase 3 Completed
921 enrolled 43 charts
Genitourinary

Hormone Refractory Prostate Cancer

NCT02043678 2025-02-19

ERA 223

Bayer

Phase 3 Completed
806 enrolled 32 charts
Genitourinary

Prostatic Neoplasms

NCT01810770 2018-09-19

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Bayer

Phase 3 Completed
243 enrolled
Genitourinary

Prostatic Neoplasms

NCT01618370 2017-03-31

Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Bayer

Phase 3 Completed
705 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡